ATE226829T1 - Pharmazeutische zusammensetzung, enthaltend serum-amyloid p-komponenten, zur prophylaxe und therapie von viralen infektionen sowie kit zur detektionvon komplexen zwischen solchen zusammensetzungen und viralen komponenten - Google Patents

Pharmazeutische zusammensetzung, enthaltend serum-amyloid p-komponenten, zur prophylaxe und therapie von viralen infektionen sowie kit zur detektionvon komplexen zwischen solchen zusammensetzungen und viralen komponenten

Info

Publication number
ATE226829T1
ATE226829T1 AT97900943T AT97900943T ATE226829T1 AT E226829 T1 ATE226829 T1 AT E226829T1 AT 97900943 T AT97900943 T AT 97900943T AT 97900943 T AT97900943 T AT 97900943T AT E226829 T1 ATE226829 T1 AT E226829T1
Authority
AT
Austria
Prior art keywords
components
viral
serum amyloid
prophylaxis
complexes
Prior art date
Application number
AT97900943T
Other languages
English (en)
Inventor
Sven-Erik Svehag
Ellen Holm Nielsen
Ove Andersen
Original Assignee
Profylakse Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Profylakse Aps filed Critical Profylakse Aps
Application granted granted Critical
Publication of ATE226829T1 publication Critical patent/ATE226829T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97900943T 1996-01-25 1997-01-24 Pharmazeutische zusammensetzung, enthaltend serum-amyloid p-komponenten, zur prophylaxe und therapie von viralen infektionen sowie kit zur detektionvon komplexen zwischen solchen zusammensetzungen und viralen komponenten ATE226829T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK7996 1996-01-25
PCT/DK1997/000035 WO1997026906A1 (en) 1996-01-25 1997-01-24 Pharmaceutical composition comprising serum amyloid p component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components

Publications (1)

Publication Number Publication Date
ATE226829T1 true ATE226829T1 (de) 2002-11-15

Family

ID=8089501

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97900943T ATE226829T1 (de) 1996-01-25 1997-01-24 Pharmazeutische zusammensetzung, enthaltend serum-amyloid p-komponenten, zur prophylaxe und therapie von viralen infektionen sowie kit zur detektionvon komplexen zwischen solchen zusammensetzungen und viralen komponenten

Country Status (10)

Country Link
US (1) US6406698B1 (de)
EP (1) EP0915707B1 (de)
AT (1) ATE226829T1 (de)
AU (1) AU712819B2 (de)
CA (1) CA2247388C (de)
DE (1) DE69716741T2 (de)
DK (1) DK0915707T3 (de)
ES (1) ES2185900T3 (de)
PT (1) PT915707E (de)
WO (1) WO1997026906A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4575897A (en) * 1996-10-11 1998-05-11 Universiteit Utrecht Pharmaceutical and diagnostic use of serum amyloid p component
US6365570B1 (en) * 1997-10-10 2002-04-02 Universiteit Utrecht Pharmaceutical and diagnostic use of Serum Amyloid P component
CN1301745A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——淀粉样糖蛋白10和编码这种多肽的多核苷酸
US6872541B2 (en) * 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US20040091503A1 (en) * 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
US7763256B2 (en) * 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US20100297074A1 (en) * 2002-12-23 2010-11-25 Richard Hans Gomer Wound healing compositions, systems, and methods
ATE422943T1 (de) * 2002-12-23 2009-03-15 William Marsh Rice Univeristy Verfahren und verbindungen zur verstärkung der fybrozyten-bildung
CA2708004C (en) 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US7592695B2 (en) * 2006-12-11 2009-09-22 Graftech International Holdings Inc. Compound heat sink
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
CA2754961C (en) 2009-03-11 2018-04-10 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
DK2405929T3 (en) 2009-03-11 2018-08-27 Promedior Inc SAP polypeptide for use in the treatment of autoimmune disorders and graft-versus-host disease
AU2010232591A1 (en) * 2009-04-01 2011-11-03 Promedior, Inc. Pulmonary and nasal delivery of serum amyloid P
TW201103972A (en) 2009-04-01 2011-02-01 Solvay Fluor Gmbh Process for the manufacture of etched items
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
JP5822826B2 (ja) 2009-06-17 2015-11-24 プロメディオール， インコーポレイテッド Ｓａｐ変異体及びその使用
US10295539B2 (en) * 2010-04-19 2019-05-21 Meso Scale Technologies, Llc. Serology assays

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221628A (en) * 1991-03-19 1993-06-22 Northwestern University Binding of aggregated immunoglobulin or immune complexes by serum amyloid P component
US5270052A (en) * 1991-04-19 1993-12-14 New England Medical Center Hospitals, Inc. Methods and compositions for treatment of infection by intracellular parasites
DE69230643T2 (de) * 1991-11-27 2000-06-21 Immtech International Inc., Evanston Methode zur behandlung von viralen infektionen
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
AU4575897A (en) * 1996-10-11 1998-05-11 Universiteit Utrecht Pharmaceutical and diagnostic use of serum amyloid p component
US5908825A (en) * 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same

Also Published As

Publication number Publication date
DK0915707T3 (da) 2003-03-03
CA2247388A1 (en) 1997-07-31
PT915707E (pt) 2003-03-31
EP0915707A1 (de) 1999-05-19
AU1438097A (en) 1997-08-20
DE69716741T2 (de) 2003-06-12
US6406698B1 (en) 2002-06-18
ES2185900T3 (es) 2003-05-01
EP0915707B1 (de) 2002-10-30
CA2247388C (en) 2009-06-02
WO1997026906A1 (en) 1997-07-31
AU712819B2 (en) 1999-11-18
DE69716741D1 (de) 2002-12-05

Similar Documents

Publication Publication Date Title
ATE226829T1 (de) Pharmazeutische zusammensetzung, enthaltend serum-amyloid p-komponenten, zur prophylaxe und therapie von viralen infektionen sowie kit zur detektionvon komplexen zwischen solchen zusammensetzungen und viralen komponenten
PT83434B (pt) Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida
MY107843A (en) Anti-viral compounds.
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
DE69818707D1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
EA199901031A1 (ru) Производные бензимидазола
MXPA02006679A (es) Composicion farmaceutica.
AU3475097A (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
DE69738351D1 (de) Verfaheren zur durch rekombinante adeno-assoziierte virus-gerichtete gentherapie
CA2111580A1 (fr) Composes immunogenes a effet notamment anti-cytokine, procede de preparation, compositions pharmaceutiques et kits les renfermant
AU4358701A (en) Methods of preventing and treating respiratory viral infeciton using immunomodulatory polynucleotide sequences
EP0270317A3 (de) Pharmaceutische Zuberatung zur Behandlung von Virus-Krankheiten
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
EP1852121A3 (de) Flüssige Analoge zur Behandlung viraler Infektionen
ATE89735T1 (de) Pharmazeutische zubereitung zur behandlung von viruskrankheiten mit leber-extrakt.
CA2372099C (en) Antiviral agent in the form of nose drops
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
HK141494A (en) Peptide fragments of HIV
BR9706938A (pt) Composto uso do mesmo formulação farmacêutica e processos para produzir o composto e para o tratamento ou a prevenção de sintomas ou efeitos de uma infecção virótica em um mamífero infectado incluindo um humano
AU6383296A (en) Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
ES2162862T3 (es) Uso de la timosina para tratar la hepatitis c en pacientes que no responden al tratamiento con interferon.
DK0885013T3 (da) Anvendelse af multipotente paramunitetsinducere fra svækkede, ikke-immunogene poxvirus eller parapoxvirus til fremstilling af lægemidler
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0915707

Country of ref document: EP

REN Ceased due to non-payment of the annual fee